Norges Bank
TLIS

Norges Bank’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

Norges Bank’s Portfolio TLIS Stock Details TLIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-667
Closed -$110K – 2355
2021
Q2 		$110K Hold
667
– – ﹤0.01% 2203
2021
Q1 		$129K Buy
+667
New +$166K ﹤0.01% 2124

Other funds holding TLIS

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NIP
Nicholas Investment Partners Rancho Santa Fe, California $1.39B AUM 97.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank's TLIS Position: Q3 2021 in Review

Norges Bank sold out of Talis Biomedical Corporation Common Stock (TLIS) in Q3 2021, closing a stake of 667 shares — an estimated $110K sold.

Norges Bank first reported a position in TLIS in Q1 2021 and held it in 2 quarters. The position peaked at $129K in Q1 2021. 38 funds tracked by Wall St. Rank hold TLIS as of Q3 2021.

  • Norges Bank reported no remaining Talis Biomedical Corporation Common Stock position as of Q3 2021 after selling out during the quarter.
  • Norges Bank sold 667 Talis Biomedical Corporation Common Stock shares in Q3 2021, an estimated $110K.
  • Norges Bank first reported a position in Talis Biomedical Corporation Common Stock in Q1 2021 and held it in 2 quarters.
  • Norges Bank's Talis Biomedical Corporation Common Stock position peaked at $129K in Q1 2021.
  • 38 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q3 2021.

Based on Norges Bank's 13F filing for Q3 2021, filed 5 Nov 2021.